Product Images Felodipine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Felodipine NDC 72162-1742 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - 1 formula
Label - lbl721621742
Felodipine Extended-Release Tablets, USP are a medication that contains 2.5mg of Felodipine. These tablets are to be taken orally and should be swallowed whole, without being crushed, cut, or chewed. They are available in a container that is tightly closed and resistant to light. The tablets should be stored at a temperature between 20°C and 25°C (68°F and 77°F). This medication is only to be dispensed by a pharmacist, and the instructions for use can be found at the provided website. The manufacturer of these tablets is Yung Shin Pharmaceutical Ind. Co., Ltd, and they were relabeled by Bryant Ranch Prepack, Inc.*
table 1 - table 1
table 2 - table 2
Percent of Patients with Adverse Events in Controlled Trials" of Felodipine Extended-Release Tablets (N = 861) as Monotherapy without Regard to Causality (Incidence of discontinuations shown in parentheses) Body System: - Peripheral Edema: 33% in placebo group, 2% in 25mg group, 88% in 5mg group, 174% in 10mg group - Asthenia: 33% in placebo group, 39% in 25mg group, 33000% in 5mg group, 22% in 10mg group - Warm Sensation: 0% in placebo group, 0% in 25mg group, 09% in 5mg group, 15% in 10mg group - Palpitation: 24% in placebo group, 04% in 25mg group, 14% in 5mg group, 25% in 10mg group - Nausea: 15% in placebo group, 12% in 25mg group, 17% in 5mg group, 1% in 10mg group - Dyspepsia: 12% in placebo group, 39% in 25mg group, 07% in 5mg group, 05% in 10mg group - Constipation: 09% in placebo group, 12% in 25mg group, 03% in 5mg group, 15% in 10mg group - Headache: 102% in placebo group, 106% in 25mg group, 11% in 5mg group, 147% in 10mg group - Dizziness: 27% in placebo group, 27% in 25mg group, 36% in 5mg group, 37% in 10mg group - Paresthesia: 15% in placebo group, 16% in 25mg group, 12000% in 5mg group, 12002% in 10mg group - Upper Respiratory Infection: 1.8% in placebo group, 39% in 25mg group, 19000% in 5mg group, 07% in 10mg group - Cough: 03% in placebo group, 08% in 25mg group, 12000% in 5mg group, 17% in 10mg group - Rhinorthea: 0% in placebo group, 16% in 25mg group, 02% in 5mg group, 02% in 10mg group - Sneezing: 0% in placebo group, 16% in 25mg group, 0% in 5mg group, 0% in 10mg group - Rash: 09% in placebo group, 2% in 25mg group, 02% in 5mg group, 02% in 10mg group - Flushing: 09% in placebo group, 39% in 25mg group, 53% in 5mg group, 69% in 10mg group Note: Patients in titration studies may have been exposed to more than one dose level of felodipine extended-release tablets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
